NanoString’s partnerships with each of these leading CROs will focus on two priorities. Firstly,
“Biopharma companies have expressed a high level of interest in our 360 Series of gene expression panels and their proprietary analysis packages,” said
The IO 360 panel is currently intended for Research Use Only, not for use in diagnostic procedures.
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.